Cargando…

Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study

PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitolins, Mara Z, Case, L Douglas, Morgan, Timothy M, Miller, Margaret A, Burke, Gregory L
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990907/
https://www.ncbi.nlm.nih.gov/pubmed/21151685
http://dx.doi.org/10.2147/IJWH.S12863
_version_ 1782192534954442752
author Vitolins, Mara Z
Case, L Douglas
Morgan, Timothy M
Miller, Margaret A
Burke, Gregory L
author_facet Vitolins, Mara Z
Case, L Douglas
Morgan, Timothy M
Miller, Margaret A
Burke, Gregory L
author_sort Vitolins, Mara Z
collection PubMed
description PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic disease risk factors, and health-related quality of life in perimenopausal and postmenopausal women. PARTICIPANTS AND METHODS: Two years after the SEA study ended participants were recontacted to complete questionnaires to quantify their health status, medications, menopausal symptoms, and their use of hormone therapy and soy-based foods and supplements. Participants were also asked to record vasomotor symptoms for seven days. RESULTS: Surveys were collected from 182 of the 241 participants who had been enrolled in the SEA study (76% response rate). Women were 55 ± 2.8 years of age, well educated (80% more than high school), and 93% reported good to excellent health. All but six reported experiencing at least one menopausal symptom, and 56% reported one or more hot flashes on one or more days. Eighty-one women (45%) continued to use soy for menopausal symptom relief, and 58 (32%) were using hormone therapy. Women taking hormone therapy were experiencing fewer and less severe hot flashes than those who were not taking hormone therapy (P < 0.001); hot flash frequency and severity did not differ significantly between those who did and did not use soy, after controlling for hormone therapy use. CONCLUSION: Most participants reported they were still experiencing menopausal symptoms. Additionally, half of the most symptomatic women (not taking hormone therapy) were still consuming soy products for vasomotor symptoms.
format Text
id pubmed-2990907
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29909072010-12-13 Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study Vitolins, Mara Z Case, L Douglas Morgan, Timothy M Miller, Margaret A Burke, Gregory L Int J Womens Health Original Research PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic disease risk factors, and health-related quality of life in perimenopausal and postmenopausal women. PARTICIPANTS AND METHODS: Two years after the SEA study ended participants were recontacted to complete questionnaires to quantify their health status, medications, menopausal symptoms, and their use of hormone therapy and soy-based foods and supplements. Participants were also asked to record vasomotor symptoms for seven days. RESULTS: Surveys were collected from 182 of the 241 participants who had been enrolled in the SEA study (76% response rate). Women were 55 ± 2.8 years of age, well educated (80% more than high school), and 93% reported good to excellent health. All but six reported experiencing at least one menopausal symptom, and 56% reported one or more hot flashes on one or more days. Eighty-one women (45%) continued to use soy for menopausal symptom relief, and 58 (32%) were using hormone therapy. Women taking hormone therapy were experiencing fewer and less severe hot flashes than those who were not taking hormone therapy (P < 0.001); hot flash frequency and severity did not differ significantly between those who did and did not use soy, after controlling for hormone therapy use. CONCLUSION: Most participants reported they were still experiencing menopausal symptoms. Additionally, half of the most symptomatic women (not taking hormone therapy) were still consuming soy products for vasomotor symptoms. Dove Medical Press 2010-11-02 /pmc/articles/PMC2990907/ /pubmed/21151685 http://dx.doi.org/10.2147/IJWH.S12863 Text en © 2010 Vitolins et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Vitolins, Mara Z
Case, L Douglas
Morgan, Timothy M
Miller, Margaret A
Burke, Gregory L
Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title_full Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title_fullStr Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title_full_unstemmed Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title_short Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
title_sort soy use and vasomotor symptoms: soy estrogen alternative follow-up study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990907/
https://www.ncbi.nlm.nih.gov/pubmed/21151685
http://dx.doi.org/10.2147/IJWH.S12863
work_keys_str_mv AT vitolinsmaraz soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy
AT caseldouglas soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy
AT morgantimothym soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy
AT millermargareta soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy
AT burkegregoryl soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy